In Focus Stocks: Eltek (NASDAQ:ELTK), Littelfuse (NASDAQ:LFUS), Cleco Corporation (NYSE:CNL), HealthEquity (NASDAQ:HQY), Celldex Therapeutics (NASDAQ:CLDX)

Eltek Ltd. (NASDAQ:ELTK) caters to the Technology space. It has a net profit margin of -2.40% and weekly performance is -9.09%. On the last day of trading company shares ended up at $1.20. Eltek Ltd. (NASDAQ:ELTK) distance from 50-day simple moving average (SMA50) is 2.47%.

Eltek Ltd. (NASDAQ:ELTK) announced its financial results for the fourth quarter and full year ended December 31, 2015. Gross profit was $6.6 million (15.8% of revenues), an increase of 8.7% compared to gross profit of $6.0 million (12.9% of revenues) in 2014.

Littelfuse Inc. (NASDAQ:LFUS) ended the last trading day at $119.65. Company weekly volatility is calculated as 1.92% and price to cash ratio as 8.03. Littelfuse Inc. (NASDAQ:LFUS) showed a weekly performance of -0.56%.

On 17 March, Littelfuse Inc. (NASDAQ:LFUS) has added a series of silicon Schottky devices designed for ultra-low forward voltage drop (VF) to its rapidly expanding power semiconductor portfolio.

On 23 March, Cleco Corporation (NYSE:CNL) shares advanced 2.08% and was closed at $47.50. CNL EPS growth in last 5 year was -12.10%. Cleco Corporation (NYSE:CNL) year to date (YTD) performance is -8.34%.

Cleco Corporation (NYSE:CNL) announced that the Louisiana Public Service Commission (LPSC) voted during its Business and Executive Session held March 22 to hold a special meeting to reconsider the proposed acquisition of Cleco on March 28 at 1 p.m.

HealthEquity, Inc. (NASDAQ:HQY) shares advanced 8.51% in last trading session and ended the day at $24.36. HQY Gross Margin is 57.60% and its has a return on assets of 8.30%. HealthEquity, Inc. (NASDAQ:HQY) quarterly performance is -6.05%.

Zacks Investment Research upgraded shares of Healthequity Inc (NASDAQ:HQY) from a hold rating to a buy rating in a research note released on Wednesday, Analyst Ratings Network.com reports. They currently have $27.00 price target on the stock.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) shares moved down -8.23% in last trading session and ended the day at $3.57. CLDX has a return on assets of -34.40%. Celldex Therapeutics, Inc. (NASDAQ:CLDX) quarterly performance is -77.67%.

On 17 March, Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced that the Company and its collaborating investigators will present seven posters with new clinical and preclinical data at the American Association for Cancer Research (AACR) Annual Meeting 2016 in New Orleans.